Patents by Inventor Dominique Louis Leon Swinnen
Dominique Louis Leon Swinnen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912721Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: GrantFiled: November 24, 2020Date of Patent: February 27, 2024Assignees: UCB Biopharma SRL, SanofiInventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Publication number: 20210155637Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: ApplicationFiled: November 24, 2020Publication date: May 27, 2021Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Patent number: 10906919Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: GrantFiled: December 14, 2018Date of Patent: February 2, 2021Assignees: UCB Biopharma SRL, SanofiInventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Publication number: 20190367535Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: ApplicationFiled: December 14, 2018Publication date: December 5, 2019Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Patent number: 10202405Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: GrantFiled: October 2, 2015Date of Patent: February 12, 2019Assignee: UCB Biopharma SPRLInventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Patent number: 10087179Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: October 2, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Gareth Neil Brace, Julien Alistair Brown, Mark Daniel Calmiano, Prafulkumar Tulshibhai Chovatia, Michael Deligny, Ellen Olivia Gallimore, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Malcolm MacCoss, Joanna Rachel Quincey, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
-
Patent number: 9932343Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: April 3, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
-
Patent number: 9890174Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: February 13, 2018Assignee: UCB BIOPHARMA SPRLInventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
-
Publication number: 20170305932Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.Type: ApplicationFiled: October 2, 2015Publication date: October 26, 2017Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
-
Publication number: 20160376268Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: ApplicationFiled: December 8, 2014Publication date: December 29, 2016Inventors: Rikki Peter ALEXANDER, Gareth Neil BRACE, Julien Alistair BROWN, Mark Daniel CALMIANO, Praful Tulshi CHOVATIA, Michael DELIGNY, Ellen Olivia GALLIMORE, Jag Paul HEER, Victoria Elizabeth JACKSON, Boris KROEPLIEN, Malcolm MAC COSS, Joanna Rachel QUINCEY, Yogesh Anil SABNIS, Dominique Louis Léon SWINNEN, Zhaoning ZHU, Uwe HEINELT, Volkmar WEHNER
-
Publication number: 20160304530Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogues thereof, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: ApplicationFiled: December 8, 2014Publication date: October 20, 2016Inventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
-
Publication number: 20160304523Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: ApplicationFiled: December 8, 2014Publication date: October 20, 2016Inventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner